Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 4/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 4/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990213 | 0.80 | KIT (0.46) | KITDDR1DDR2 | |
| SCHEMBL6316118 | 0.80 | GRM5 (0.44) | DYRK1ASCN5ATGFBR1EGLN2KIT | |
| SCHEMBL1997076 | 0.78 | APP (0.41) | DYRK1ASCN5ATGFBR1KITDDR1 | |
| SCHEMBL9902614 | 0.77 | SCN5A (0.40) | DYRK1ASCN5ATGFBR1EGLN2MAPK14 | |
| SCHEMBL6322323 | 0.77 | DYRK1A (0.40) | DYRK1ASCN5ATGFBR1EGLN2KIT | |
| SCHEMBL4553627 | 0.75 | DYRK1A (0.39) | DYRK1ASCN5ATGFBR1EGLN2KDM1A | |
| SCHEMBL259223 | 0.75 | EGLN2 (0.46) | DYRK1ASCN5AEGLN2KDM1A | |
| SCHEMBL1990791 | 0.75 | EGLN2 (0.45) | DYRK1ASCN5ATGFBR1EGLN2KDM1A | |
| SCHEMBL6757648 | 0.75 | GRM5 (0.51) | TGFBR1 | |
| SCHEMBL1990408 | 0.75 | PDE10A (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | GASTER LARAMIE MARY (GB) | 2005-01-20 | — | — | US | disclosed |
| US-20040220230-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. | 2004-11-04 | — | — | US | disclosed |
| EP-1444232-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030166633-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-09-04 | — | — | US | disclosed |
| WO-2003042211-A1 | PHENYL SUBSTITUTED TRIAZOLES AND THEIR USE AS SELECTIVE INHIBORS OF AKL5 KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-1257543-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM PLC (GB) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001062756-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014938-A1 | Phenyl substituted triazoles and their use as selective inhibitors of akl5 kinase | AKR1C3, CBR3, PHKG1 | DYRK1A 847/4885SCN5A 595/4885TGFBR1 2245/4885 |
| US-20030166633-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | DYRK1A 1633/4885SCN5A 805/4885TGFBR1 431/4885 |
| US-20040220230-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | DYRK1A 1644/4885SCN5A 839/4885TGFBR1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.